To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
|
Subjects aged 45-84 years at time of consent
|
|
Intended to undergo a standard-of-care screening colonoscopy
|
|
Considered by a physician or healthcare provider as being of 'average risk' for CRC
|
|
Willing to consent to blood draw prior to bowel preparatory procedures or undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw.
|
|
Willing to consent to follow-up for one year as per protocol
|
|
Able and willing to sign informed consent
|
|
Undergoing colonoscopy for investigation of CRC risk symptoms
|
|
Has undergone colonoscopy within preceding 9 years
|
|
Positive FIT/FOBT result within the previous 12 months (+/- 3 months)
|
|
Has completed Cologuard or Epi proColon testing within the previous 3 years.
|
|
Has undergone a CT colonography in the prior 4 years.
|
|
History of colorectal cancer.
|